Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
about
Application of Bioactive Quercetin in Oncotherapy: From Nutrition to NanomedicineDietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseasesThe pharmacokinetics of anthocyanins and their metabolites in humans.Bioavailability challenges associated with development of anti-cancer phenolics.Microsomal quercetin glucuronidation in rat small intestine depends on age and segment.3,4-Dihydroxyphenylacetic acid, a microbiota-derived metabolite of quercetin, attenuates acetaminophen (APAP)-induced liver injury through activation of Nrf-2.Electrophiles in foods: the current status of isothiocyanates and their chemical biology.Colonic metabolites of berry polyphenols: the missing link to biological activity?Berry flavonoids and phenolics: bioavailability and evidence of protective effects.Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo.Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update.Comparison of the urinary excretion of quercetin glycosides from red onion and aglycone from dietary supplements in healthy subjects: a randomized, single-blinded, cross-over study.A novel tag-free probe for targeting molecules interacting with a flavonoid catabolite.Quercetin Metabolites Up-Regulate the Antioxidant Response in Osteoblasts Isolated From Fetal Rat Calvaria.Oral bioavailability of quercetin from different quercetin glycosides in dogs.Radiolabelled cyanidin 3-O-glucoside is poorly absorbed in the mouse.Quercetin metabolites and protection against peroxynitrite-induced oxidative hepatic injury in rats.Systematic review of the effects of the intestinal microbiota on selected nutrients and non-nutrients.3,4-Dihydroxyphenylacetic acid is a potential aldehyde dehydrogenase inducer in murine hepatoma Hepa1c1c7 cells.Synthesis of polyhydroxylated flavonoids bearing a lipophilic decyl tail as potential therapeutic antioxidants
P2860
Q26770108-243E18A3-839B-478B-AC6C-5373CC1DF08FQ27002456-8216695D-7A3E-4F57-A8D6-D3530C46E1D3Q33842761-8BE6C355-9DA7-490E-834B-BA4FEBE35A7CQ34057398-F6642198-55C1-44E0-A9D9-13388C82762AQ35122803-2480E038-4135-46A0-BDC3-9DD3B534391BQ35941776-E496BC55-3B6A-46D4-9BE5-FD50C6B99688Q37688791-0FA64452-089D-473D-A827-5EC485884DE9Q37801022-75964B16-0E03-49E6-95B1-F6D5864C3975Q37801023-E86344DF-53A0-4AF7-BC0C-B4616C857074Q37902937-F67D0BB7-49E2-4E6E-B9D6-EED5B1958B03Q38245598-AD6D6EEB-40EF-4396-806F-84DB0536F453Q41127173-D0AEEE12-8F44-46C5-B8AE-A8CECD6DB0EFQ41682888-530F76FF-7736-4F2B-8F91-DA518F70E882Q42702455-47B490BF-0AC8-4241-8114-D0CF33084651Q43129212-5ED7C7FB-5615-44CB-A30C-03FDE20F8945Q43148116-F3DA69DC-A104-4108-BA4C-F2929B43A1A0Q43294351-6461C7A3-4231-457B-A7AB-CF8913C4340CQ46271930-1A211F77-C948-4BC2-90FD-8ABF9F9AF121Q51803435-AD65111D-8B2D-4260-A7BC-A466F4A8638CQ57090620-0CC91631-6F5E-4A4B-AD5D-D64EEFEE647F
P2860
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bioavailability of [2-
@nl
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@ast
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@en
type
label
Bioavailability of [2-
@nl
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@ast
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@en
prefLabel
Bioavailability of [2-
@nl
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@ast
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@en
P2093
P50
P356
P1476
Bioavailability of [2-(14)C]quercetin-4'-glucoside in rats.
@en
P2093
Alan Crozier
Cyril Auger
Jean-Max Rouanet
Micheal E J Lean
Pierre-Louis Teissèdre
P304
12127-12137
P356
10.1021/JF802754S
P407
P577
2008-12-01T00:00:00Z